Gauss Expands Series C Funding to $ 30 Million
Gauss, a developer of computer vision applications for healthcare based in Menlo Park, Calif., has raised additional funding of $ 10 million.
The additional financing, which brings the total Series C financing round to $ 30 million, was led by The 4100 Group, a subsidiary of Delta Dental of Michigan and Ohio, with additional participation from existing investors. , including SoftBank Ventures Asia, Northwell Health, Providence Health and Services. , OSF Healthcare and Polaris Partners. The 4100 Group Managing Director of Private Market Investments, Scott Lancaster, MD, MBA, will join Gauss’s Board of Directors.
The company will use the funds to continue advancing its rapid home COVID-19 antigen test and computer vision app. Gauss plans to announce clinical trial results soon and the technology is already being used to fuel large-scale home research studies on COVID-19.
Founded in 2011 and led by CEO Siddarth Satish, Gauss is the leader in computer vision in healthcare. Its flagship product, Triton, uses computer vision to detect surgical and obstetric hemorrhages in real time and alerts clinicians who can intervene and treat in a timely manner. Triton received De Novo clearance from the U.S. Food and Drug Administration (FDA) in 2014, as the first-ever computer vision software for surgical use, and multiple 510 (k) tracking clearances. Available on iPhone, Triton has been widely adopted by healthcare systems in the United States.
Last month, the company announced an exclusive partnership with Cellex, a biotechnology company specializing in point-of-care diagnostic testing, to launch a rapid home and point-of-care COVID-19 antigen test. If cleared by the Food and Drug Administration (FDA) under Emergency Use Clearance (EUA), the test would be the first to allow people to test themselves for active infection with the COVID-19 and receive rapid results in their own homes or similar user environments.